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Abstract
Many women would prefer fewer bleeding episodes while taking oral contraceptives. For this reason
and with the intention of reducing menstruation-associated symptoms, an extended-cycle contraceptive
is considered in the present paper. However, it remains unknown whether this long-term treatment is
associated with a different breast cancer risk from that of the usual treatment. Therefore, in the present
in vitro work we intend to compare the effect of these different treatment regimens on breast cancer risk.
MCF-7 cells (human estrogen- and progesterone-receptor-positive metastatic breast cancer cells) and
HCC1500 cells (human estrogen- and progesterone-receptor-positive primary breast cancer cells) were
incubated with physiological concentrations of ethinylestradiol (EE). Usual and extended cycles were
mimicked by incubation periods of 18 hours with EE followed by 6 hours without EE and 24 hours with
EE for 3 days, respectively. In both cell lines, EE elicited a significant increase in the proliferation rate.
No significant difference was found between the two incubation periods. Our results indicate that
continuously administered ethinylestradiol may not increase breast cancer risk in comparison to
intermittent application. However, clinical studies are necessary to prove these in vitro results.
Comparison of the proliferative effects of ethinylestradiol in an intermittent and 
a continuous dosing regime on human breast cancer cells 
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Summary 
Many women would prefer fewer bleeding episodes when taking oral contraceptives. 
For this reason and with the intention to reduce menstruation associated symptoms 
an extended – cycle contraceptive is currently considered. However it remains 
unknown whether this long-term treatment is associated with a different breast 
cancer risk as compared to the usual treatment. Therefore in the present in vitro work 
we intended to compare the effect of these different treatment regimens on breast 
cancer risk. 
MCF-7 cells (human estrogen- and progesterone-receptor positive metastatic breast 
cancer cells) and HCC1500 cells (human estrogen- and progesterone-receptor 
positive primary breast cancer cells) were incubated with physiologic concentrations 
of ethinylestradiol (EE2). Usual and extended cycle were mimicked by incubation 
periods of 18 h with EE2 followed by 6 h without EE2 and 24 h EE2 for 3 days, 
respectively. 
In both cell lines EE2 elicited a significant increase in the proliferation rate. No 
significant difference was found between the two incubation periods.  
Our results indicate that continuously administered ethinylestradiol may not increase 
breast cancer risk as compared to intermittent application. However clinical studies 
are necessary to prove these in vitro results. 
 
Key Words: Ethinylestradiol, breast cancer cells, proliferation, continuous incubation, 
intermittent incubation  
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Introduction 
The role of estrogens in tumor development was marked out as a promoting rather 
than an initiating one since estrogens are able to stimulate the proliferation of target 
cells such as breast epithelial cells. This can result in an increase in DNA mutations 
due to the high mitotic rate [1]. Recent studies provide evidence, that estrogens not 
only can promote cancer, but also may initiate mutations by certain metabolites [1].  
Whether compounds may have a stimulatory or inhibitory effect on breast cancer 
development or growth is often evaluated in studies with established breast cancer 
cell lines, like MCF-7. Estrogens stimulate breast cell proliferation and established 
breast cancer risks such as early age at menarche, late menopause and hormone 
replacement therapy are indicative of a greater lifetime estrogen exposure.  
Combined oral contraceptives (COC) contain ethinylestradiol (EE2), a potent 
synthetic estrogen with higher affinity to the estrogen receptor and longer persistence 
in the body than estradiol (E2) [2].  
Epidemiologic studies of the association between COC and breast cancer are not 
consistent. A pooled analysis combining 54 studies reported no association between 
past COC use and breast cancer, however breast cancer may increase with use of 
COC at younger ages and COC use might cause earlier diagnosis [3-5]. The studies 
included women using the conventional treatment regimes of COC with 21 days 
treatment followed by a treatment free interval of 7 days. 
The 21-day regime of oral contraceptives mimics the natural cycles by causing a 
monthly menstrual bleeding. However there is no scientific reason for a 21- day 
regime of combined oral contraceptives (COC). Many women would prefer fewer 
bleeding episodes [6]. For this reason and with the intention to reduce menstruation 
associated symptoms an extended – cycle contraceptive has been developed and 
approved in the U.S (Seasonale ®). The dosing regime consists of 84 days of active 
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pills followed by 7 days of placebo. Many gynaecologists in Germany and 
Switzerland use an extended regime of COC in women with menstrual problems or 
symptomless women, who find an extended regime with less menstruations more 
comfortable [7]. Because in European countries extended cycle pills regimes are not 
approved different ethinylestradiol-progestagen preparations are prescribed 
containing 20-30mcg ethinylestradiol. The duration of continuous pill intake varies 
from 42-168 days [8]. Although these regimes are described to be more comfortable 
for many women it has to be considered, that extended-pill-cycles are associated 
with an about 30% increase of the monthly hormone dosage. Clinical trials on the 
safety of the new regimes particularly the risk of breast cancer are not available [9]. 
To receive long-term epidemiologic data will take years. Breast cancer initiation 
occurs many years before presentation of the disease. Therefore it is important to 
study the effect of the new dosage regime of EE2 on pre-existing breast cancer cells. 
With the present study we intended to further explore these uncertainties in vitro. For 
the first time we investigated the effect of ethinylestradiol, the estrogen currently used 
in combined contraceptives, in an intermittent and a continuous regime on the well – 
known breast cancer cell line MCF7 cells and estrogen-receptor positive HCC 1500 
primary breast cancer cells. 
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Materials and Methods 
17α-ethinylestradiol (EE2) was purchased from Sigma Chemical Co., Munich, 
Germany. The compound was dissolved in ethanol and was stored as concentrated 
stock solution at -20°C. 
The MCF-7 cells were acquired from DSMZ, Braunschweig, Germany. Prior to the 
experiment, the MCF-7 cells were maintained in 5% FCS in DMEM (Gibco BRL, 
Eggenstein, Germany) supplemented with 0.3 mg/ml glutamine, 5 ng/ml bovine 
insulin and 100 U/ml penicillin plus 100 µg/ml streptomycin. 
HCC1500, a human estrogen and progesterone receptor-positive primary breast 
cancer cell line was purchased from ATCC. Cells were maintained in RPMI-1640 
medium (without phenol red) purchased from Sigma, which was modified to contain 1 
mM sodium pyruvate, 2 mM L-glutamine, 4.5 g/L glucose, 10% (v/v) heat inactivated 
foetal bovine serum and 100 U/ml penicillin plus 100 μg/ml streptomycin. 
All assays were conducted using charcoal/dextran-treated serum-containing medium 
(without phenol red) for MCF-7 and HCC1500 cells. Stock concentrations of EE2 
were further diluted with these assay media during working experiments to give a 
final ethanol concentration of less than 0.01% per well.  
To simulate the two in vivo conditions, i.e. intermittent and continuous therapy, the 
following time frames were used: For intermittent incubation the cells were incubated 
for 3 days with the steroid for 18 h and then steroid-free medium was used for 6 h. 
For imitating continuous therapy the cells were incubated with EE2 for 24 h for 3 
consecutive days.   
 
Ninety-six well plates were seeded with approximately 1000 cells per well. The cells 
were incubated for the appropriate time frame at 37°C in culture medium. EE2 was 
tested in the concentrations of 0.1 nM (10-10M) and 1nM (10-9M). 
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Cell proliferation was measured by the ATP chemosensitivity test, where proliferation 
is quantified by measuring light emitted during the bioluminescence reaction of 
luciferene in the presence of ATP and luciferase. This assay has been validated in 
the routine laboratory of our hospital, where it has been in use for several years to 
evaluate the efficacy of chemotherapy agents for the treatment of breast cancer 
patients. In previous experiments we have compared this assay with established 
proliferation assays such as crystal violet assay and BrdU assay and found equal 
changes, but a more better reproducibility for the ATP assay. 
 
Statistical analysis 
Proliferation was measured versus controls and performed in triplicates in three 
independent experiments. Within and between statistical analysis was done by 
ANOVA with the logarithmic values followed by Dunnett’s procedure for within group 
comparisons and Bonferroni’s correction for between group comparisons. The overall 
alpha level was set at 0.05. The statistical software used was JMP (Version 3.2.1) by 






As seen in Figure 1 for the MCF-7 cells, EE2 significantly stimulated the proliferation 
of the cells by both incubation schemes. The values were 49 and 54 % at the 
concentration of 0.1 nM and 28 and 39% at the concentration of 1 nM for the 
intermittent and continuous incubation time, respectively. There was no significant 
difference between both schemes.  
In Figure 2 the results for the HCC 1500 cells are depicted. Similarly to the MCF-7 
cells, both incubation modes elicited a significant stimulation of the proliferation. The 
corresponding values were 31.5 and 38.2 % for 0.1 nM and 29.4 and 33.6% for 1 nM. 








Nowadays it is well known, that estrogens promote the growth of breast tumor cells 
[10]. The results of our in vitro experiments show, that EE2 elicits a pattern of 
proliferation on the receptor-positive breast cancer line MCF-7 and on HCC1500 cells 
in both an intermittent and a continuous dosing regime. The ethinylestradiol 
concentrations used for stimulation in our study were in the range from 10-9 – 10-10M, 
because clinically relevant concentrations of ethinylestradiol found in COC users are 
in the order of 4.6x10-10M [11].  
Various breast cancer cell lines (MCF-7;T47D) have been used to study the role of 
both estrogens and progestagens on cellular proliferation in order to determine their 
potential tumor risk. These studies clearly showed a stimulating effect by estrogens 
[12-15]. Proliferation of malignant cells is under control of estrogen and growth 
factors. The current meaning is, that estrogens act proliferatively in a paracrine 
fashion by inducing production of stromal derived growth factors and cytokines or 
their receptors via activation of epithelial or stromal estrogen receptors [15]. 
Only few data are available on the effect of ethinylestradiol on breast cancer cell 
lines. Ethinylestradiol differs substantially from estradiol, because it suppresses the 
endogenous estradiol synthesis and the ethinylgroup on C-17 of ethinylestradiol 
blocks C-17 and C-16 oxidation [16]. In the liver EE2 induces the synthesis of 
proteins controlling coagulation and fibrinolysis. Furthermore the synthesis of binding-
globulins is increased. Sex hormone–binding globulin which has been suggested to 
reduce estradiol-mediated cell growth in MCF-7 breast cancer cells increases by 
more than100% in users of contraceptives pills [17]. 
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In vivo ethinylestradiol plasma levels reach a steady-state between day seven and 
ten of the pill cycle and decrease during the 7- day pause of the normal pill cycle [18]. 
Since in users of the long-cycle this decrease of ethinylestradiol is missing, it can be 
hypothesised that the pharmacokinetic of SHBG is different during the long-cycle. 
Different SHBG levels may on the other hand cause different effects on the growth of 
MCF-7 cells. 
Previously it has been shown, that in comparison to estradiol EE2 elicits a weaker 
effect on MCF-7 cells than estradiol at the concentration of 10-10M [19]. Interpreting 
these data it has to be considered, that in women using COC breast cells are 
exposed to ethinylestradiol and the endogen produced estrogens, too.  
In the present study we focused on different dosing regimen of ethinylestradiol, 
because a new continuous contraceptive pill for the long-cycle has been approved. 
Lippert et al. demonstrated, that the continuous and the sequential combined 
hormone replacement therapy exert different effects in vitro on MCF-7 cells [20-22]. 
These regimen do investigate changes in the addition of a progestagen to estradiol, 
while the estrogen is administered continuously. In contrast to these results with a 
combined regime, we did not find different stimulation of MCF-7 and HCC1500 cells 
using continuous or intermittent stimulation with EE2 alone.  
Taking our results into account it has to be considered for future studies, that 
synthetic progestagens too exert variable effects on proliferation of tumor cell lines 
depending on the dosis and the type of progestagen. There is evidence, that the 19-
nortestosterone derivatives in COC have estrogenic properties and activation of 
estrogen receptor is the growth stimulatory mechanism for these synthetic progestins 
[12,23]. The progestagen levonorgestrel used in the long-cycle regime is a 19-
nortestosterone derivate and breast cancer cell stimulation caused by ethinylestradiol 
in different dosage regimes might be modified by this progestagen.  
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Limitations of our study are, that cell culture studies are a means of observing trends 
and mechanistic effects which are not easily obtained otherwise. However these 
studies require careful interpretation since culture conditions play an important role in 
determining the results. Using the same cell model and conditions as in the present 
experiment we could verify similar results e.g. for actions of estradiol in different 
experiments [20-22]. A cell culture model cannot reproduce the complex clinical 
situation, but can reflect many characteristics of the original tissue such as enzyme 
and receptor types so that one can focus on individual factors possibly involved in the 
in vivo situation. A model can attempt to approximate the clinical situation and help in 
the elucidation of possible mechanisms involved but never replace prospective 
clinical or epidemiological studies. Insofar our results are preliminary and do not allow 
yet the recommendation of the long-cycle to healthy women. On the other hand our 
data do not force us, to change the clinical practice of prescribing the long-cycle in 
women with gynaecological problems like severe dysmenorrhoea, menstrual-related 
headache, premenstrual syndrome and severe endometriosis. 
 
Conclusion 
Our results indicate that continuously administered ethinylestradiol stimulates breast 
cell proliferation to the same degree as intermittent application of ethinylestradiol. In 
order to evaluate further which COC - regimen might be more safe for breast cancer 
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Figure 1: Changes of proliferation of MCF-7 cells after addition of ethinylestradiol 
continuously (Cont) or intermittently (Inter) for 3 consecutive days as compared to 
controls (C). (Means ± SD) 
 
Figure 2: Changes of proliferation of HCC 1500 cells after addition of ethinylestradiol 
continuously (Cont) or intermittently (Inter) for 3 consecutive days as compared to 
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